Immunic announces publication of extended data from phase 2 emphasis trial of vidofludimus calcium in relapsing-remitting multiple sclerosis in the peer reviewed journal, neurology® neuroimmunology & neuroinflammation

– 30 mg and 45 mg daily doses of vidofludimus calcium suppressed development of gadolinium-enhancing lesions by 78% and 74% compared to pooled placebo at 24 weeks – – improvements in serum neurofilament light chain consistent with recently announced interim phase 2 calliper data in progressive multiple sclerosis – – twin phase 3 ensure trials in relapsing multiple sclerosis and phase 2 calliper trial in progressive multiple sclerosis remain underway – new york , april 30, 2024 /prnewswire/ -- immunic, inc. (nasdaq: imux), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced that data from its phase 2 emphasis trial of lead asset, vidofludimus calcium (imu-838), in patients with relapsing-remitting multiple sclerosis (rrms) has been published online on april 25, 2024 in neurology® neuroimmunology & neuroinflammation, an official journal of the american academy of neurology. the paper, lead authored by coordinating investigator, robert j.
IMUX Ratings Summary
IMUX Quant Ranking